We used immunohistochemistry (6 HT vs 6 controls) to confirm the protein expression of CCL2 and CXCL10 in the thyroid and found that HT patients had significantly higher levels of CCL2 and CXCL10 than controls (P < 0.01), as illustrated in Figure 2. The gene discussed is CCL2; the disease is hematocrit.